Comparative Outcomes of Fluticasone‑Based vs Budesonide Dual Inhalers in COPD

Investigators reported comparative outcomes among US adults aged 40 years or older with chronic obstructive pulmonary disease (COPD) who initiated one of three inhaled corticosteroid–long-acting β-agonist (ICS–LABA) single-inhaler products in propensity-matched cohort comparisons of ICS–LABA inhalers. The analysis prespecified two time-to-event outcomes: time to first moderate or severe COPD exacerbation and time to first pneumonia hospitalization, evaluated across pairwise product comparisons.

The authors described a pairwise, new-user cohort analysis using US insurance claims data. They conducted 1:1 propensity-score matching separately for each inhaler comparison and used Cox proportional hazards models to estimate time-to-event associations. The three products were once-daily dry powder fluticasone furoate–vilanterol, twice-daily metered-dose budesonide–formoterol, and twice-daily dry powder fluticasone propionate–salmeterol (each assessed at the moderate strength approved for COPD, as described). Follow-up was structured as an on-treatment analysis, with censoring tied to outcome occurrence, treatment discontinuation, switching or adding maintenance inhalers, disenrollment, or death. The article also reports additional prespecified and post hoc checks intended to assess robustness to alternative follow-up and outcome definitions. Across these matched cohorts, the comparisons were presented as estimates of relative differences between products under the study’s specified design choices.

For the primary effectiveness outcome (first moderate or severe COPD exacerbation), the investigators reported that fluticasone furoate–vilanterol was associated with a lower hazard than budesonide–formoterol (HR 0.91; 95% CI 0.88–0.94) and than fluticasone propionate–salmeterol (HR 0.94; 95% CI 0.89–0.98). Fluticasone propionate–salmeterol and budesonide–formoterol were reported to have a similar hazard (HR 0.98; 95% CI 0.95–1.01). The article also reported a 365-day number needed to treat estimate of 40 for the comparisons where presented, along with absolute event rates and risk differences at 365 days in its results tables. Overall, the reported between-product differences in time to first exacerbation were characterized as modest associations observed in propensity-matched cohorts.

For the primary safety outcome (first pneumonia hospitalization), the authors reported hazard ratios close to null across pairwise comparisons: fluticasone furoate–vilanterol vs budesonide–formoterol (HR 1.03 [95% CI 0.96–1.11]), fluticasone furoate–vilanterol vs fluticasone propionate–salmeterol (HR 0.93 [95% CI 0.85–1.03]), and fluticasone propionate–salmeterol vs budesonide–formoterol (HR 1.04 [95% CI 0.98–1.10]). The authors summarized these as showing no clear differences across products. The article reported that subgroup analyses (including strata reflecting baseline disease severity measures, prior exacerbation history, eosinophil categories, co-occurring asthma, spirometry receipt, and prescriber specialty) and sensitivity analyses (including alternative grace periods, as-started follow-up, exclusion of early events, shorter follow-up windows, and varied outcome definitions, as well as high-dimensional propensity score matching) generally showed patterns consistent with the primary analyses. The limitations section noted the possibility of residual confounding in claims-based observational work, constraints from unavailable clinical factors (such as spirometry measures like FEV1 and insurance plan type), potential misclassification of COPD, substantial discontinuation leading to shorter follow-up, and differences across cohorts that could affect generalizability.

Key Takeaways:

• In propensity-matched, pairwise comparisons, once-daily fluticasone furoate–vilanterol was associated with a modestly lower hazard of first moderate or severe COPD exacerbation versus each twice-daily comparator.
• Pneumonia hospitalization risk was reported as similar across all three pairwise inhaler comparisons.
• Subgroup and sensitivity analyses were reported as generally consistent with the main findings, and the authors noted observational and claims-data limitations that shape interpretation.